한글목차

진토제 시장은 2025년에는 31억 7,000만 달러, 2032년에는 48억 6,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 6.3%를 나타낼 전망입니다.

메스꺼움은 종종 구토 충동을 동반하는 불온한 감각이며, 일상 생활에 큰 지장을 초래합니다. 현대 의료의 중요한 측면인 메스꺼움 의학은 고통스러운 증상을 완화하고 전반적인 웰빙을 개선하는 것을 목표로 합니다. 액제, 패치 등 다양한 형태가 있습니다. 진토제는 수용체를 효과적으로 차단함으로써 멀미, 화학 요법으로 인한 메스꺼움, 임신 관련 불편함 및 기타 관련 질환으로 고통받는 환자에게 필요한 완화를 제공합니다.

시장 역학 :

메스꺼움의 유병률 증가, 약물 제형의 진보, 노인 인구 증가, 연구 개발 활동의 활성화가 예측 기간 중 세계의 진토제 시장의 성장을 가속할 것으로 예측됩니다. Vanda Pharmaceuticals Inc.는 멀미 치료제에 대한 3상 임상시험 결과를 발표하여, 멀미 구토 예방에 도움이 된다는 이전에 발표된 연구 결과를 확인했습니다.

그러나 부작용과 안전성에 대한 우려, 진토제의 고비용, 특정 원인을 겨냥한 치료법의 부족, 일부 사례의 제한적인 효율성 등이 예측 기간에 있어서 세계의 진토제 시장의 성장을 방해할 것으로 예측됩니다.

본 조사의 주요 특징

• 본 보고서는 진토제 세계 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 복합연간 성장률(CAGR%)을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 해명해, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 설명하고 있습니다.
• 또 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터에 근거해, 진토제 세계 시장에 있어서의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 통찰은 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 할 수있게합니다.
• 진토제 세계 시장 보고서는 투자자, 공급업체, 제품 제조 업체, 유통 업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 진토제 시장의 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
• 진토제 증가
  • 억제요인
• 부작용과 안전성에 대한 우려
  • 기회
• 표적 치료법의 개발
  • 주요 하이라이트
  • 규제 시나리오
  • 최근 동향
  • 제품 출시/승인
  • PEST 분석
  • PORTER 분석
  • 합병, 인수 및 제휴

제4장 세계의 진토제 시장, 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 진토제 시장, 약제 클래스별, 2020년-2032년

• 항히스타민제
• 항콜린제
• 세로토닌 길항제
• 도파민 길항제
• 칸나비노이드
• 기타

제6장 세계의 진토제 시장, 투여 경로별, 2020년-2032년

• 경구
• 주사제
• 경피
• 직장
• 기타

제7장 세계의 진토제 시장, 유통 채널별, 2020년-2032년

• 소매 약국
• 병원 약국
• 온라인 약국
• 기타

제8장 세계의 진토제 시장, 지역별, 2020년-2032년

• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • ASEAN
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙 아프리카
  • 남아프리카

제9장 경쟁 구도

• 기업 프로파일
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi SA
  • Merck &Co., Inc.
  • Johnson &Johnson
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Eli Lily and Company

제10장 섹션

• 참고문헌
• 조사 방법
• 미국과 서비스에 대해

영문목차

Nausea Medicine Market is estimated to be valued at USD 3.17 Bn in 2025 and is expected to reach USD 4.86 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.3% from 2025 to 2032.

Nausea is an unsettling sensation that is often accompanied by the urge to vomit, which can significantly disrupt a daily life. Nausea medicine which is a vital aspect of modern healthcare, aims to alleviate the distressing symptom and improve overall well-being. The medicine that is designed to target body's specific receptors is responsible for nausea and vomiting. These medications come in various forms, including pills, liquids and patches. By effectively blocking the receptors, nausea medicine provides the needed relief to patients who are suffering from motion sickness, chemotherapy-included nausea, pregnancy-related discomfort, and other related conditions. This introduction delves into the importance of these medicines in enhancing quality of life for individuals plagued by nauseous episodes.

Market Dynamics:

Increasing prevalence of nausea, advancements in drug formulations and increasing geriatric population, increasing research and development activities is anticipated to drive growth of the global nausea medicine market over the forecast period. Moreover, growing awareness and diagnosis is also expected to boost the growth of the global nausea medicine market over the forecast period. Development of targeted therapies, expansion into emerging markets, combination therapies and non-pharmacological interventions are expected to create growth opportunities for the global nausea medicine market during the forecast period.For instance, in May 2023, Vanda Pharmaceuticals Inc., a worldwide biopharmaceutical company, revealed the results of its Phase III research of tradipitant in motion sickness, thereby confirming the previously published findings that tradipitant is beneficial in the prevention of motion sickness vomiting. The Phase III study was carried out on boats in U.S. coastal waters under real-world situations.

However, adverse effects and safety concerns, high cost of nausea medicines, lack of targeted therapies for specific causes and limited efficiency in some cases are expected to hamper growth of the global nausea medicine market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global nausea medicine market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nausea medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Eli Lilly and Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nausea medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analysing the global nausea medicine market

Detailed Segmentation:

• Global Nausea Medicine Market, By Drug Class:
  • Antihistamines
  • Anticholinergics
  • Serotonin Antagonists
  • Dopamine Antagonists
  • Cannabinoids
  • Others
• Global Nausea Medicine Market, By Route of Administration:
  • Oral
  • Injectable
  • Transdermal
  • Rectal
  • Others
• Global Nausea Medicine Market, By Distribution Channel:
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others
• Global Nausea Medicine Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Eli Lilly and Company

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Increasing prevalence of nausea
  • Restraints
• Adverse effects and safety concerns
  • Opportunities
• Development of targeted therapies
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Nausea Medicine Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Nausea Medicine Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Antihistamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Anticholinergics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Serotonin Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Dopamine Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cannabinoids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Other
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Nausea Medicine Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Transdermal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Rectal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Nausea Medicine Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Nausea Medicine Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Bn)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 -2032, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 -2032, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • GlaxoSmithKline plc
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Pfizer Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novartis International AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sanofi S.A.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck &Co., Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Johnson & Johnson
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bayer AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Takeda Pharmaceutical Company Limited
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • AstraZeneca plc
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Eli Lily and Company
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies

10. Section

• References
• Research Methodology
• About us and Services